The combination showed a strongly synergistic interaction in KRAS-mutant lung cancer cells compared with wild-type cancer cells, and KRAS-mutant lung cancer cells were more sensitive to this combination than AZ628 or BP-1-102 single. This evidence concerns the gene KRAS and lung carcinoma.